A novel strategy for cancer gene therapy: RNAi

Qiuwei Pan, Rong Cai, Xinyuan Liu, Cheng Qian*

*Corresponding author for this work

Research output: Contribution to journalReview articlePopular

11 Citations (Scopus)

Abstract

RNA interference (RNAi) induces gene silencing at a level of posttranscription mediated by double stranded RNA. There are numerous methods for delivery of small double-stranded interference RNA (siRNA) to the target cells, including nonviral and viral vectors. Among these methods, viral vectors are the more efficient vehicles. The expression of short hairpin RNA (shRNA) by viral vectors in target cells can be cut by Dicer enzyme to become ∼21 bp siRNA, which could guide degradation of cognate mRNA. RNAi technology can be directed against cancer using a variety of strategies, including the inhibition of overexpressed oncogenes, promoting apoptosis, regulating cell cycle, antiangiogenesis and enhancing the efficacy of chemotherapy and radiotherapy. Since RNAi technology has become an excellent strategy for cancer gene therapy, this review outlines the latest developments and applications of such a novel technology.

Original languageEnglish
Pages (from-to)1145-1151
Number of pages7
JournalChinese Science Bulletin
Volume51
Issue number10
DOIs
Publication statusPublished - May 2006
Externally publishedYes

Bibliographical note

Funding Information:
Acknowledgements This work was supported by the National Basic Research Program (973 Program) (Grant No. 2004CB518804).

Fingerprint

Dive into the research topics of 'A novel strategy for cancer gene therapy: RNAi'. Together they form a unique fingerprint.

Cite this